Amtagvi – Talk Bio

Actionable Insights Powered by AI

TScan Cuts Workforce by 30% While Iovance Advances Amtagvi Program Amid Layoffs

1 month ago talkbio0Tagged Amtagvi, Cell Therapy, Iovance Biotherapeutics, layoffs, Lymphocytes, Tumor-Infiltrating, Malignant neoplasm of lung, melanoma, strategic restructuring, TScan Therapeutics

TScan Therapeutics; layoffs; Iovance Biotherapeutics; Amtagvi; tumor-infiltrating lymphocyte (TIL) therapy; melanoma; lung cancer; strategic restructuring; biotech layoffs; cell therapy

FDA Approves Amtagvi as the First One-time Cell Therapy for Solid Tumors: A Groundbreaking TIL Immunotherapy for Advanced Melanoma

2 years ago talkbio0Tagged Amtagvi, Lymphocytes, Tumor-Infiltrating, Solid Neoplasm, United States Food and Drug Administration

Amtagvi, Solid Neoplasm, United States Food and Drug Administration, Lymphocytes, Tumor-Infiltrating